Annual report pursuant to Section 13 and 15(d)

Income Taxes - Schedule of Components of Deferred Tax Assets (Details)

v3.22.0.1
Income Taxes - Schedule of Components of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Net operating loss carryforwards $ 67,719 $ 47,549
Research and development credits 31,864 25,175
Deferred revenue   3,629
Accruals and other 3,973 2,965
Operating lease liability 7,266  
Stock based compensation 3,910 3,495
Fixed asset basis 1,008 917
Total deferred tax assets 115,740 83,730
Less: valuation allowance (100,646) (74,432)
Gross deferred tax assets 15,094 9,298
Deferred tax liabilities:    
Operating lease right-of-use asset (6,716)  
Vaxcyte investment (8,378) (9,298)
Total deferred tax liabilities (15,094) (9,298)
Total net deferred tax assets $ 0 $ 0